文献速递胸部肿瘤乳腺癌支持与姑息治疗

1996-2014年中国癌症经济负担:系统综述

[Economic burden of cancer in China during 1996-2014: a systematic review].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2016-01-01

该系统综述检索1996-2014年CNKI、万方和PubMed数据库,纳入91项研究,分析中国癌症经济负担研究现状。多数研究为医院为基础的个体调查,仅考虑直接医疗费用;每例患者费用多在1万至3万元,日均费用在所有常见癌症中均呈3-7倍增长;

要点

  • 纳入91项研究,其中32项关于肺癌,超过半数发表于近5年。
  • 83项个体调查中77项为医院为基础的费用调查,多数仅计直接医疗费用。
  • 每例患者费用多为1万至3万元,肺癌和乳腺癌差异较大(1万至9万元)。

核心结论

  • 1996-2014年中国癌症经济负担证据有限且可比性弱,尤其在人群层面,报告的每例患者费用可能被低估。

研究设计与样本

  • 系统综述,检索CNKI、万方和PubMed数据库1996-2014年文献,关键词包括癌症、经济负担、支出、费用,经排除程序后纳入91项研究。
  • 对纳入研究的研究对象与数据来源、方法学、主要结果进行结构化摘录,所有费用数据按中国医疗保健消费价格指数折算为2013年价值。

主要发现

  • 超过半数纳入研究发表于近5年,32项研究关于肺癌。
  • 83项个体调查中77项为医院为基础,通过个体病历摘录获取数据,多数仅考虑直接医疗费用。
  • 每例患者费用和日均费用是最常用的结局指标。
  • 每例患者费用多数在1万至3万元人民币,肺癌和乳腺癌差异较大(1万至9万元),食管癌和胃癌差异较小(1万至5万元),宫颈癌趋势最稳定(几乎所有值低于2万元)。

局限性

  • 1996-2014年中国癌症经济负担证据有限且可比性弱,尤其在人群层面。
  • 报告的每例患者费用可能被低估。
  • 多数个体调查为医院为基础且仅考虑直接医疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the current status of research on economic burden of cancer in China from 1996 to 2014. Methods: The key words including cancer, economic burden, expenditure, cost were used to retrieve the literatures published in CNKI and Wanfang (the two most commonly used databases for literature in Chinese) and PubMed during 1996-2014. A total of 91 studies were included after several exclusionary procedures. Information on subjects and data source, methodology, main results were structurally abstracted. All the expenditure data were discounted to year of 2013 value using China's health care consumer price indices. Results: More than half of the included studies were published over the past 5 years, 32 of the studies were about lung cancer. Among the 83 individual-based surveys, 77 were hospital-based and obtained data via individually medical record abstraction, and most of which only considered the direct medical expenditure. Expenditure per cancer patient and expenditure per diem were the most commonly used outcome indicators. Majority of the findings on expenditure per cancer patient ranged from 10 thousands to 30 thousands Chinese Yuan (CNY), with larger disparity in lung and breast cancer (ranged from 10 thousands to 90 thousands CNY), narrower difference in esophageal and stomach cancer (ranged from 10 thousands to 50 thousands CNY), and most stable trend in cervical cancer (almost all the values less than 20 thousands CNY). Without exception, the expenditures per diem for all the common cancers were increasing over the period from 1996 to 2014 (3-7 fold increase). Only 8 population-level economic burden studies were included and the reported expenditure of cancer at national level ranged from 32.6 billions to 100.7 billions CNY. Conclusions: Evidence on economic burden of cancer in China from 1996 to 2014 are limited and weakly comparable, particularly at a population level, and the reported expenditure per patient may be underestimated.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shi JF, Shi CL, Yue XP, et al. [Economic burden of cancer in China during 1996-2014: a systematic review]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998471. doi:10.3760/cma.j.issn.0253-3766.2016.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。